ANVS
Annovis Bio, Inc.
NYSE · USHealthcareBiotechnology
$1.69-2.87%
Price as of Jul 20, 2026
ANVS financials
Annovis Bio, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $29.7M | $26.7M | $45.0M | $25.5M |
| Operating income | -$29.7M | -$26.7M | -$45.0M | -$25.5M |
| Net income | -$28.9M | -$24.6M | -$56.2M | -$25.3M |
| EBITDA | -$28.9M | -$22.7M | -$56.2M | -$25.3M |
| Basic EPS | $-1.40 | $-2018.50 | $-6.23 | $-3.10 |
| Diluted EPS | $-1.40 | $-2009.77 | $-6.23 | $-3.10 |
| Balance sheet | ||||
| Cash & equivalents | $19.5M | $10.6M | $5.8M | $28.4M |
| Total assets | $21.1M | $13.9M | $10.2M | $36.0M |
| Total liabilities | $4.2M | $4.6M | $18.0M | $7.7M |
| Stockholders’ equity | $16.9M | $9.3M | -$7.8M | $28.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Net debt | -$19.5M | -$10.6M | -$5.8M | -$28.4M |
| Cash flow | ||||
| Operating cash flow | -$25.6B | -$21.9B | -$40.0M | -$17.3M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$25.6B | -$21.9B | -$40.0M | -$17.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |